<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05057455</url>
  </required_header>
  <id_info>
    <org_study_id>BIRUNI 2</org_study_id>
    <nct_id>NCT05057455</nct_id>
  </id_info>
  <brief_title>Effectiveness of the Cytokine Hemadsorption on Sepsis</brief_title>
  <official_title>Effectiveness of the Cytokine Hemadsorption on the Clinical Progression and Mortality of Intensive Care Patients With Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biruni University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biruni University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective study, we aimed to compare the laboratory and clinical results of&#xD;
      cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis&#xD;
      or septic shock.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">February 15, 2021</completion_date>
  <primary_completion_date type="Actual">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>IL-6</measure>
    <time_frame>1 YEARS</time_frame>
    <description>levels of IL-6</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">39</enrollment>
  <condition>Interleukin-6</condition>
  <arm_group>
    <arm_group_label>ICU patients diagnosed with sepsis or septic shock</arm_group_label>
    <description>compare the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cytokine hemadsorption</intervention_name>
    <description>the laboratory and clinical results of cytokine hemadsorption as an immunomodulation therapy in ICU patients diagnosed with sepsis or septic shock.</description>
    <arm_group_label>ICU patients diagnosed with sepsis or septic shock</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        In this one-centered study, we prospectively analyzed the outcomes and laboratory findings&#xD;
        of 39 patients diagnosed with sepsis from 01 Jan 2020 to 30 December 2020 hospitalized in&#xD;
        ICU.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  the patients were the available data of clinical and laboratory diagnosis of sepsis&#xD;
             and septic shock&#xD;
&#xD;
          -  detection of gram-negative bacterial agent in blood or sputum culture.&#xD;
&#xD;
          -  patients who had the shock symptoms such as hypotension, tachycardia or fever during&#xD;
             the course of sepsis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  had uncontrolled hemorrhage,&#xD;
&#xD;
          -  diagnosed with cardiac failure at stage 4 or renal failure at stage 4 or hepatic liver&#xD;
             failure at stage 4&#xD;
&#xD;
          -  cancer at the end stage or admitted with acute coronary syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ilke Kupeli</name>
      <address>
        <city>Istanbul</city>
        <zip>34250</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Bahar İ, Oksuz H, Şenoğlu N, Demirkiran H, Aydoğan M, Tomak Y, Çömez M, Bayrakçı S, Gönüllü E, Berktaş M. Compliance With the Surviving Sepsis Campaign Bundle: A Multicenter Study From Turkey. Cureus. 2021 May 12;13(5):e14989. doi: 10.7759/cureus.14989.</citation>
    <PMID>34131534</PMID>
  </reference>
  <results_reference>
    <citation>Houschyar KS, Pyles MN, Rein S, Nietzschmann I, Duscher D, Maan ZN, Weissenberg K, Philipps HM, Strauss C, Reichelt B, Siemers F. Continuous hemoadsorption with a cytokine adsorber during sepsis - a review of the literature. Int J Artif Organs. 2017 May 29;40(5):205-211. doi: 10.5301/ijao.5000591. Epub 2017 May 19. Review.</citation>
    <PMID>28525674</PMID>
  </results_reference>
  <results_reference>
    <citation>Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10. Review.</citation>
    <PMID>32283152</PMID>
  </results_reference>
  <results_reference>
    <citation>Bonavia A, Groff A, Karamchandani K, Singbartl K. Clinical Utility of Extracorporeal Cytokine Hemoadsorption Therapy: A Literature Review. Blood Purif. 2018;46(4):337-349. doi: 10.1159/000492379. Epub 2018 Sep 3. Review.</citation>
    <PMID>30176653</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Biruni University</investigator_affiliation>
    <investigator_full_name>IKUPELI</investigator_full_name>
    <investigator_title>investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

